CTLA4 and neoplasm: In 2021, Adam et al. showed that treatment with anti-CTLA-4 + anti-PD-1 in tumour bearing mice from a genetic background (B6/lpr mice) prone to autoimmune responses, induced multiple organ irAEs [155].